secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001683168-26-003161
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health rebrands as Valion Bio; ticker to VBIO; targets BARDA SNS procurement for Entolimod
--------------------------------------------------------------------------------

- Corporate name changes to Valion Bio, Inc.; Nasdaq ticker to change from TIVC to VBIO effective April 28, 2026.
- Lead asset Entolimod (TLR5 agonist) for Acute Radiation Syndrome has FDA Fast Track, Orphan Drug, and Animal Rule designations.
- Engaged with BARDA, DTRA, NIAID for Strategic National Stockpile procurement; potential nine-figure non-dilutive revenue event.
- Parallel oncology indication: chemotherapy-induced neutropenia; targeting Phase IIb readiness; market over $22B.
- Velocity Bioworks CDMO subsidiary (acquired ~$16.3M) completed 200-fold scale-up; offers independent third-party revenue stream.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826003161/0001683168-26-003161-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826003161/tivic_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-003161

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer